LATITUDE

Understanding the Recent Advances in Treating Castrate Sensitive Prostate Cancer 

Understanding the Recent Advances in Treating Castrate Sensitive Prostate Cancer 

Abiraterone, enzalutamide, apalutamide, and docetaxel could be considered for this patient population (castrate sensitive prostate cancer patients), noted Taplin. "None of us can [confirm] that one [option] is better than the other; [the treatment decision] needs to be individualized [by weighing the] pros and cons [with each agent] for each patient," Taplin concluded.